Antihistamine/Decongestant Combination (Oral Route)Drug Information provided by: Micromedex
US Brand Names
Canadian Brand Names
In November 2000, the Food and Drug Administration (FDA) issued a public health warning regarding phenylpropanolamine (PPA) due to the risk of hemorrhagic stroke. The FDA, supported by results of a research program, requested that manufacturers voluntarily discontinue marketing products that contain PPA and that consumers work with their healthcare providers to select alternative products.
Antihistamine and decongestant combinations are used to treat the nasal congestion (stuffy nose), sneezing, and runny nose caused by colds and hay fever.
Antihistamines work by preventing the effects of a substance called histamine, which is produced by the body. Histamine can cause itching, sneezing, runny nose, and watery eyes. Antihistamines contained in these combinations are:
- acrivastine, azatadine, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, dexbrompheniramine, diphenhydramine, loratadine, pheniramine, phenyltoloxamine, promethazine, pyrilamine, and triprolidine.
The decongestants, such as phenylephrine, and pseudoephedrine, produce a narrowing of blood vessels. This leads to clearing of nasal congestion, but it may also cause an increase in blood pressure in patients who have high blood pressure.
Some of these combinations are available only with your doctor's prescription. Others are available without a prescription; however, your doctor may have special instructions on the proper dose of the medicine for your medical condition.
Do not give any over-the-counter (OTC) cough and cold medicine to a baby or child under 2 years of age. Using these medicines in very young children might cause serious or possibly life-threatening side effects .
This product is available in the following dosage forms:
- Tablet, Chewable
- Tablet, Extended Release
- Capsule, Extended Release
- Tablet, Disintegrating
- Suspension, Extended Release
- Tablet, Extended Release, 24 HR
- Capsule, Extended Release, 24 HR